Table Of Contents:
Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
Chapter 3. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market: By Vector Type Market Trends, Size, and Future Outlook
- By Vector Type Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Vector Type Definitions, Technology Landscape
- By Vector Type Market Drivers
- Product Launches
- Technology Launches
- By Vector Type Market Restraints
Chapter 4. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market: By Disease Indication Market Trends, Size, and Future Outlook
- By Disease Indication Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Disease Indication Definitions, Technology Landscape
- By Disease Indication Market Drivers
- Product Launches
- Technology Launches
- By Disease Indication Market
Chapter 5. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market: By Gene Type Market Trends, Size, and Future Outlook
- By Gene Type Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Gene Type Definitions, Technology Landscape
- By Gene Type Market Drivers
- Product Launches
- Technology Launches
- By Gene Type Market Restraints
Chapter 6. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market: By Route of Administration Market Trends, Size, and Future Outlook
- By Route of Administration Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Route of Administration Definitions, Technology Landscape
- By Route of Administration Market Drivers
- Product Launches
- Technology Launches
- By Route of Administration Market Restraints
Chapter 7. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market: By End-User Market Trends, Size, and Future Outlook
- By End-User Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By End-User Definitions, Technology Landscape
- By End-User Market Drivers
- Product Launches
- Technology Launches
- By End-User Market Restraints
Chapter 8. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market: By Manufacturing Process Market Trends, Size, and Future Outlook
- By Manufacturing Process Market Size (US$), CAGR (%), and Forecast (2022-2030)
- By Manufacturing Process Definitions, Technology Landscape
- By Manufacturing Process Market Drivers
- Product Launches
- Technology Launches
- By Manufacturing Process Market Restraints
Chapter 9. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market: Regional Market Trends, Size, and Future Outlook
-
- North America
- Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Market Drivers and Restraints
- Europe
- Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Market Drivers and Restraints
- Asia Pacific
- Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Market Drivers and Restraints
- Latin America
- Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Market Drivers and Restraints
- Middle East & Africa
- Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Market Drivers and Restraints
- North America
Chapter 10. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market: Competitive Landscape
- Novartis AG
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- BioMarin Pharmaceutical Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Spark Therapeutics, Inc. (Acquired by Roche)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Audentes Therapeutics, Inc. (Acquired by Astellas Pharma)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- UniQure N.V.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Asklepios BioPharmaceutical, Inc. (AskBio)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- REGENXBIO Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Voyager Therapeutics, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Solid Biosciences Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Abeona Therapeutics Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Adverum Biotechnologies, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Apic Bio
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Freeline Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- LogicBio Therapeutics, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Sarepta Therapeutics, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Pfizer Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Amicus Therapeutics, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Biogen Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Sangamo Therapeutics, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Genera Bio
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
Appendix
- About Us
Frequently Asked Questions
The current market size of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy industry is estimated to be around USD 1.2 billion.
1) Increasing prevalence of genetic disorders, 2) Rising demand for personalized medicine, 3) Favorable regulatory environment for approvals, 4) Increasing investments in gene therapy research and development, 5) Advancements in gene editing technologies, 6) Development of novel AAV serotypes, 7) Expansion of gene therapy applications, 8) Increasing strategic collaborations and partnerships, 9) Improving healthcare infrastructure in emerging markets, 10) Increasing awareness and acceptance levels.
1) High cost of gene therapies, 2) Potential safety concerns and risks, 3) Challenges in manufacturing and scaling-up, 4) Limited availability of skilled workforce, 5) Ethical and regulatory challenges, 6) Long development timelines and high failure rates, 7) Limited reimbursement coverage.
The leading component segment in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market is the AAV9 subsegment, widely used for treating neurological disorders due to its ability to cross the blood-brain barrier.
The major players operating in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market include Novartis AG, BioMarin Pharmaceutical Inc., Spark Therapeutics, Inc., Audentes Therapeutics, Inc., UniQure N.V., Asklepios BioPharmaceutical, Inc. (AskBio), REGENXBIO Inc., Voyager Therapeutics, Inc., Solid Biosciences Inc., Abeona Therapeutics Inc., and others.
The North America region is expected to lead the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market, with a projected CAGR of around 30% and a market size of over $2.5 billion by 2031.
1) Increasing prevalence of genetic disorders, 2) Rising demand for personalized medicine, 3) Favorable regulatory environment for approvals, 4) Increasing investments in gene therapy research and development, 5) Advancements in gene editing technologies, 6) Development of novel AAV serotypes, 7) Expansion of gene therapy applications, 8) Increasing strategic collaborations and partnerships.